DAWN Day One Biopharmaceuticals, Inc.: Earnings per share for the last 12 months

Day One is expanding its influence in oncology through licensing alliances with global biopharma behemoths. Historical EPS YoY TTM dynamics confirm the stability of the course, while -0.50 reflects the latest value of the metric. Dominance in the pediatric segment precludes price wars, ensuring high margins. Business growth relies on the commercialization of Augtyro and expansion into the therapy of pediatric brain tumors.

This indicator measures the annual change in net income per share over the last twelve months, allowing investors to filter out short-term volatility and assess the actual efficiency of the business capitalization. By analyzing the EPS TTM YoY trend, one can determine the extent to which robotic screening and AI-driven biomarker analysis at Day One (DAWN) are effectively reducing drug development costs, converting technological superiority into financial results.